Those are big numbers and potentially big profits. So it is clear that
fat is indeed driving the biotech bus, with Galectin, Intercept, Gilead
and Raptor in the front seats and vying to take control of the wheel.
Click here to receive free email updates on Galectin Therapeutics' developments: http://www.tdmfinancial.com/emailassets/galt/galt_landing.php
SOURCE: Emerging Growth LLC